StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
380550.KQ$13240.00-5.43%
Fair $13240.00+0.0%

380550.KQ

380550.KQ

Healthcare / Health Information ServicesKOSDAQ

$13240.00

-760.00 (-5.43%)

Fairly Valued+0.0%Fair Value $13240.00Fund rank 30/100 · Data gapFallback financials|
SA 26/D
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 24%

FCF escenarios

weak_data · normalized FCF $-13.0B · quality 72.7/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 37/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

26/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -1.2%, below the 5% threshold
Thesis & Journal · 380550.KQLocal privado en este navegador · 380550.KQ
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$160.1B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-115.1%

↓

Gross Margin

100.0%

↑

Debt/Equity

0.28

↑
52-Week Range$13240
$10150$36700

TradingView lightweight chart

380550.KQ price, volumen y niveles de valoración

Último $13,240Periodo -34.8%
Fair value: $13,240

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+59.3%

FCF CAGR

—

FCF margin

-588.6%

FCF / Net income

0.69x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.62B · net income $-22.39B · FCF $-15.39B

2022-FY → 2025-FY

Gross margin

100.0%-2.5% pts

Operating margin

-632.8%+821.8% pts

Net margin

-856.2%+1974.9% pts

FCF margin

-588.6%+594.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.62B$2.62B$2.22B$1.56B$647.3M
Net Income$-22.39B$-22.39B$-15.10B$5.26B$-18.32B
EBITDA$-20.36B$-20.36B$-10.39B$8.58B$-15.51B
EPS——-4091.00-1236.00-5081.00
Gross Margin100.0%100.0%100.0%91.5%102.5%
Operating Margin-632.8%-632.8%-661.0%-753.0%-1454.6%
Net Margin-856.2%-856.2%-681.4%336.9%-2831.1%
Balance Sheet
Debt/Equity0.280.28-0.03-0.05-0.05
Current Ratio8.048.04———
Cash Flow
Free Cash Flow$-15.39B$-15.39B$-13.01B$-9.29B$-7.66B
Returns
ROE-115.1%-115.1%29.5%-14.4%41.9%
Valuation
P/B7.867.86———
Growth & Yield
Revenue Growth18.0%18.0%41.9%141.4%—
EPS Growth——-231.0%75.7%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total -34.8%

Total return

-34.8%

Start / end P/E

n/dx → n/dx

EPS bridge

-4091.00 → n/d

Residual

-34.8%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-34.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.